VANFLYTA (quizartinib)
Acute Myeloid Leukemia
ApprovedCommercial
Key Facts
About Daiichi Sankyo
Daiichi Sankyo is a Japanese pharmaceutical giant with over 125 years of medical innovation, operating in 30+ countries and publicly traded on the Tokyo Stock Exchange. The company has pivoted strategically to become a global oncology leader by 2030, leveraging its breakthrough DXd ADC technology platform. With flagship products like ENHERTU (developed with AstraZeneca) showing exceptional results across multiple cancer types, Daiichi Sankyo represents one of the most promising ADC technology platforms in oncology today.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| ASP2215 (gilteritinib) | Astellas Pharma | Approved |
| Vyxeos | Jazz Pharmaceuticals | Commercial |
| KT-253 | Kymera Therapeutics | Phase 1 |